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A recent article in the NEJM [1] illustrates the case vign-
ette of a male smoker being seen at a routine health check-
up that prompted him to enquiry about quitting using
e-cigarettes.
He is 29 years old, but with a significant medical history
of obesity (current BMI = 31), hypertension (current BP
is 128/76 mmHg on chlorthalidone 25 mg daily) and
childhood seizures. The rest of the physical examination
and the review of his systems were unremarkable.
The patient started smoking when he was 15 years old,
and he has been smoking up to 1.5 packs per day for the
past 6 years. He has reduced or stopped smoking several
times in the past using various nicotine replacement ther-
apies (NRTs) or by quitting ‘‘cold turkey’’. On each
occasion, he was able to sustain his efforts for up to
3 weeks before relapsing into his previous smoking habits.
There follows a discussion about the danger of smoking
and potentially useful smoking cessation aids. The patient
has friends who have stopped smoking cigarettes by
switching to regular use of e-cigarettes. He is now
interested in giving up smoking by trying e-cigarettes, and
asks for an opinion.
The Editorial staff at the NEJM invites two experts to
provide their personal recommendations.
Expert no. 1 is Christopher Bullen, a professor of Public
Health at the Faculty of Medical and Health Sciences of the
University of Auckland. His research interests focus pri-
marily on tobacco control and innovative smoking cessa-
tion interventions research, including e-cigarettes. He also
has wider interests in research on population health edu-
cation, and heart disease prevention and treatment. He
directs the National Institute for Health Innovation (NIHI).
He recommends trying e-cigarettes for smoking cessa-
tion because he thinks that the patient has limited phar-
macologic treatment options (contraindications for
bupropion and varenicline prescription due to his history of
seizures; inability to abstain from smoking on several
occasions despite being on NRT).
Expert no. 2, is Stanton Glantz, a professor of Medicine
in the Division of Cardiology, and American Legacy
Foundation Distinguished Professor of Tobacco Control.
He conducts research on a wide range of topics ranging
from the health effects of second hand smoke (with par-
ticular emphasis on the cardiovascular system) to the effi-
cacy of different tobacco control policies. His work has
recently expanded to include e-cigarettes. He directs the
Center for Tobacco Control Research and Education at the
University of California, San Francisco (UCSF) School of
Medicine.
He tries to convince the patient that he should reconsider
his interest in giving up smoking by trying e-cigarettes by
applying a motivational approach based on the results of
a—flawed—meta-analysis showing that these products are
not proven to assist smoking cessation [2]. The meta-
analysis took studies that contained no useful information
& Riccardo Polosa
polosa@unict.it
1 Centro Prevenzione e Cura del Tabagismo, Azienda
Ospedaliero Universitaria ‘‘Policlinico-V. Emanuele’’,
Catania, Italy
2 Dipartimento di Medicina Clinica e Sperimentale, Universita`
di Catania, Catania, Italy
3 UOC di Medicina Interna e d’Urgenza, Azienda Ospedaliero
Universitaria ‘‘Policlinico-V. Emanuele’’, Catania, Italy
123
Intern Emerg Med (2017) 12:129–131
DOI 10.1007/s11739-016-1537-0
on whether vaping helps smokers to quit, and misreported
them as if they were showing that vaping undermines
quitting. These were primary studies that compared
smokers who tried vaping, but continued to smoke with
smokers who did not try vaping. Smokers who tried vaping
and successfully stopped smoking were excluded, so
treatment efficacy was evaluated only on treatment fail-
ures. In relation to the patient’s case, he does not provide
any solution besides suggesting to stop using conventional
cigarettes (easier said than done).
We (Dr. R. Polosa and Dr. P. Caponnetto) run one of
Italy’s busiest smoking cessation centers, and have helped
thousands of smokers who successfully quit with several
methods including e-cigarettes. We were the first in the
world to publish a smoking cessation study, a RCT, and the
longest clinical follow-up with e-cigarettes. According to a
recent bibliometric analysis [3], we have been ranked as
the top most prolific authors who published in the field of
e-cigarettes.
We were pleased to see featured this case study of a
29-year-old man interested in giving up smoking
by switching to e-cigarettes in the NEJM, and we would
like to offer our personal opinion, bringing into the debate
the combined experience of an experienced internist (R.
Polosa) with that of a clinical psychologist who is in charge
of multimodal smoking cessation programs (P.
Caponnetto).
The case study presented is more challenging than
actually appears for several reasons.
The patient is relatively young, and quit rates in young
adults are known to be very low as proven by his history of
frequent relapses. There is no evidence demonstrating the
efficacy of FDA-approved smoking cessation drugs for
young adults. Thus, FDA-approved smoking cessation
drugs cannot be recommended for young adults.
The patient’s history indicates that he is at high risk of
relapse. While international guidelines place great
emphasis on relapse prevention, very little can be done to
manage smokers with a history of frequent relapses [4]. If
the patient is willing, increasing the intensity and fre-
quency of cessation counseling or adding another first line
medication may increase success rates. Nevertheless, as
mentioned earlier, there is no evidence to support the
recommendation of smoking cessation medications for
young adults who smoke.
The patient is already overweight, and is being treated
for hypertension. Stopping smoking is known to lead to
weight gain in four out of five quitters. Hence, it is
important to consider that he—if successful—will have to
deal with the burden of post-cessation weight gain with its
important negative health consequences, particularly in
consideration of the fact that obesity and hypertension are
well known risk factors for cardiovascular disease.
While there is no doubt that stopping smoking will result
in considerable health improvements, the patient requires
an alternative approach. An additional option is to
encourage him to switch to a much cleaner source of
nicotine. Given that his personal preference is to try e-ci-
garettes to quit smoking, his choice should be respected,
and the health care provider should offer a balanced
overview of their risk/benefit ratio [5].
More specifically, relevant to this patient’s clinical his-
tory, it is worth noticing that (1) e-cigarettes have helped
abstaining from conventional cigarette young adults as well
as older ones [6]; (2) e-cigarettes have been shown to
reduce post-cessation weight gain in quitters [7]; (3)
smokers with elevated blood pressure who quit by
switching to e-cigarettes may lower their BP in the long-
term [8].
Physicians should advise smokers about the most
effective ways to quickly reduce their risk. While smoking
cessation may be the most desirable final outcome from a
health point of view, it may be the wrong goal if it leads to
failure or relapse. Physicians should consider all the
pathways available to a smoking patient, and select the
ones that give the greatest probability of eliminating
exposure to tobacco smoking, including e-cigarettes. There
is now increasing evidence that—for many smokers—the
best outcome may be a long-term switch to vaping, toler-
ating the small residual risk in return for a higher likeli-
hood of success.
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